NO20043158L - Substituerte kinazolinderivater som inhibitorer av aurorakinaser - Google Patents

Substituerte kinazolinderivater som inhibitorer av aurorakinaser

Info

Publication number: NO20043158L
Authority: NO; Norway
Prior art keywords: aurorakinases; inhibitors; quinazoline derivatives; substituted quinazoline; substituted
Prior art date: 2001-12-24

Application number

NO20043158A

Other languages

English (en)

Other versions

NO328159B1 (no

Inventor

Frederic Henri Jung

Georges Rene Pasquet

Original Assignee

Astrazeneca Ab Global Ip

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-24

Filing date

2004-07-23

Publication date

2004-09-16

2004-07-23 Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip

2004-09-16 Publication of NO20043158L publication Critical patent/NO20043158L/no

2009-12-21 Publication of NO328159B1 publication Critical patent/NO328159B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20043158A 2001-12-24 2004-07-23 Substituerte kinazolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom. NO328159B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01403357		2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en)	2001-12-24	2002-12-20	Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (2)

Publication Number	Publication Date
NO20043158L true NO20043158L (no)	2004-09-16
NO328159B1 NO328159B1 (no)	2009-12-21

Family

ID=8183051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043158A NO328159B1 (no)	2001-12-24	2004-07-23	Substituerte kinazolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom.

Country Status (31)

Country	Link
US (2)	US7402585B2 (no)
EP (1)	EP1463506B1 (no)
JP (1)	JP4498741B2 (no)
KR (1)	KR101029281B1 (no)
CN (1)	CN100491372C (no)
AR (1)	AR038052A1 (no)
AT (1)	ATE446093T1 (no)
AU (1)	AU2002353196B2 (no)
BR (1)	BRPI0215312B8 (no)
CA (1)	CA2471577C (no)
CY (1)	CY1109681T1 (no)
DE (1)	DE60234125D1 (no)
DK (1)	DK1463506T3 (no)
ES (1)	ES2333702T3 (no)
HU (1)	HU229477B1 (no)
IL (1)	IL162541A0 (no)
IS (1)	IS2758B (no)
MX (1)	MXPA04006260A (no)
MY (1)	MY141739A (no)
NO (1)	NO328159B1 (no)
NZ (1)	NZ533440A (no)
PL (1)	PL211694B1 (no)
PT (1)	PT1463506E (no)
RU (1)	RU2323215C2 (no)
SA (1)	SA03230531B1 (no)
SI (1)	SI1463506T1 (no)
TW (1)	TWI335818B (no)
UA (1)	UA82058C2 (no)
UY (1)	UY27604A1 (no)
WO (1)	WO2003055491A1 (no)
ZA (1)	ZA200404923B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1330444B1 (en)	2000-11-01	2011-03-23	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic compounds and process for making them
SI1463506T1 (sl) *	2001-12-24	2010-01-29	Astrazeneca Ab	Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
WO2004006846A2 (en)	2002-07-15	2004-01-22	Exelixis, Inc.	Receptor-type kinase modulators and methods of use
ATE438644T1 (de) *	2002-12-24	2009-08-15	Astrazeneca Ab	Chinazolinderivate
BRPI0409427A (pt) *	2003-04-16	2006-04-18	Astrazeneca Ab	composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
US20060135541A1 (en) *	2003-06-02	2006-06-22	Astrazeneca Ab	(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) *	2003-06-17	2005-02-16	Astrazeneca Ab	Chemical compounds
US20060178318A1 (en) *	2003-07-03	2006-08-10	Shubha Anand	Use of aurora kinase inhibitors for reducing the resistance of cancer cells
JP4828421B2 (ja) *	2003-08-14	2011-11-30	アレイバイオファーマ、インコーポレイテッド	受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
CA2744997A1 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and method of use
CA2542076C (en) *	2003-10-14	2013-02-26	Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted tricyclic compounds as protein kinase inhibitors
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
EP1694686A1 (en) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Kinase inhibitors
WO2005105788A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
SI1746999T1 (sl)	2004-05-06	2012-01-31	Warner Lambert Co	4-fenilamino-kinazolin-6-il-amidi
DE602005024274D1 (de)	2004-07-16	2010-12-02	Sunesis Pharmaceuticals Inc	Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
EP1778669A2 (en) *	2004-08-18	2007-05-02	Takeda San Diego, Inc.	Kinase inhibitors
TW200624431A (en)	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
MX2007004403A (es)	2004-10-12	2007-04-27	Astrazeneca Ab	Derivados de quinazolina.
ATE479687T1 (de) *	2004-10-15	2010-09-15	Takeda Pharmaceutical	Kinaseinhibitoren
MX2007005857A (es)	2004-11-17	2007-10-10	Mikana Therapeutics Inc	Inhibidores de cinasa.
GB0427917D0 (en) *	2004-12-21	2005-01-26	Astrazeneca Ab	Chemical compounds
JP5075624B2 (ja)	2005-04-28	2012-11-21	田辺三菱製薬株式会社	シアノピリジン誘導体及びその医薬としての用途
GB0510963D0 (en) *	2005-05-28	2005-07-06	Astrazeneca Ab	Chemical compounds
JP2009502801A (ja) *	2005-07-22	2009-01-29	サネシスファーマシューティカルズ，インコーポレイテッド	Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン
WO2007041358A2 (en) *	2005-09-30	2007-04-12	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
GB0601215D0 (en) *	2006-01-21	2006-03-01	Astrazeneca Ab	Chemical compounds
CA2637658C (en)	2006-01-23	2012-07-17	Amgen Inc.	Aurora kinase modulators and method of use
US7560551B2 (en)	2006-01-23	2009-07-14	Amgen Inc.	Aurora kinase modulators and method of use
US7868177B2 (en)	2006-02-24	2011-01-11	Amgen Inc.	Multi-cyclic compounds and method of use
EP1994024A2 (en) *	2006-03-02	2008-11-26	AstraZeneca AB	Quinoline derivatives
UY30183A1 (es)	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
BRPI0708850A2 (pt) *	2006-03-20	2011-06-21	Hoffmann La Roche	derivados de ftalazinona pirazol, sua produção e uso como agentes farmacêuticos
CA2645583A1 (en)	2006-03-20	2007-09-27	F. Hoffman-La Roche Ag	Methods of inhibiting btk and syk protein kinases
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609617D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
US20070287706A1 (en) *	2006-05-18	2007-12-13	Dickson John K Jr	Certain substituted quinolones, compositions, and uses thereof
GB0619342D0 (en) *	2006-09-30	2006-11-08	Vernalis R&D Ltd	New chemical compounds
JPWO2008041767A1 (ja)	2006-10-05	2010-02-04	萬有製薬株式会社	ＡｕｒｏｒａＡ阻害剤の薬効を予測又は診断する遺伝子・タンパク質マーカー
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
JP2010505961A (ja) *	2006-10-09	2010-02-25	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
EP2137177B1 (en)	2007-04-05	2014-05-07	Amgen, Inc	Aurora kinase modulators and method of use
JP2010529193A (ja) *	2007-06-11	2010-08-26	ミイカナセラピューティクスインコーポレイテッド	置換ピラゾール化合物
CA2694284A1 (en) *	2007-06-29	2009-01-08	Jennifer Cossrow	Heterocyclic compounds useful as raf kinase inhibitors
EP2262796A1 (en)	2008-03-04	2010-12-22	Vitae Pharmaceuticals, Inc.	Aurora kinase inhibitors
AU2009226024B2 (en)	2008-03-20	2012-07-12	Amgen Inc.	Aurora kinase modulators and method of use
WO2010019473A1 (en)	2008-08-14	2010-02-18	Amgen Inc.	Aurora kinase modulators and methods of use
KR101733773B1 (ko)	2009-01-16	2017-05-10	엑셀리시스, 인코포레이티드	Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
CA2751886C (en) *	2009-02-11	2017-08-29	Merck Patent Gmbh	Novel amino azaheterocyclic carboxamides
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
EP2465842A1 (de) *	2010-12-17	2012-06-20	Sika Technology AG	Amine mit sekundären aliphatischen Aminogruppen
EA023998B1 (ru)	2011-03-04	2016-08-31	Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
MX2014011115A (es)	2012-03-16	2015-03-13	Axikin Pharmaceuticals Inc	Inhibidores de 3,5-diaminopirazol cinasa.
CN104024246B (zh) *	2012-03-27	2016-03-02	广东东阳光药业有限公司	作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
TWI592417B (zh)	2012-09-13	2017-07-21	葛蘭素史克智慧財產發展有限公司	胺基喹唑啉激酶抑制劑之前藥
AR092530A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
JP6301374B2 (ja) *	2013-02-21	2018-03-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	キナーゼ阻害剤としてのキナゾリン類
CN104098551B (zh) *	2013-04-03	2019-03-22	广东东阳光药业有限公司	作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
LT3046584T (lt)	2013-09-16	2017-10-10	Astrazeneca Ab	Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CA2929188C (en)	2013-11-20	2022-08-09	Signalchem Lifesciences Corp.	Quinazoline derivatives as tam family kinase inhibitors
HUE053653T2 (hu)	2014-03-26	2021-07-28	Astex Therapeutics Ltd	FGFR inhibitor és IGF1R inhibitor kombinációi
ES3014202T3 (en)	2014-03-26	2025-04-21	Astex Therapeutics Ltd	Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MY191736A (en)	2014-12-23	2022-07-13	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
HRP20201157T1 (hr)	2015-09-23	2020-11-13	Janssen Pharmaceutica N.V.	Triciklički heterocikli za liječenje raka
RU2747644C2 (ru)	2015-09-23	2021-05-11	Янссен Фармацевтика Нв	Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
CN112939948B (zh) *	2019-12-11	2022-05-17	苏州美诺医药科技有限公司	新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es)	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (no)	1994-11-12	1997-12-01	Zeneca Ltd
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
ATE294796T1 (de) *	1998-10-08	2005-05-15	Astrazeneca Ab	Chinazolin derivate
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
AU7301000A (en) *	1999-09-21	2001-04-24	Astrazeneca Ab	Quinazoline derivatives and their use as pharmaceuticals
GB0006864D0 (en) *	2000-03-21	2000-05-10	Smithkline Beecham Plc	New use
EP1299381B1 (en) *	2000-06-28	2008-05-07	AstraZeneca AB	Substituted quinazoline derivatives and their use as inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
SI1463506T1 (sl) *	2001-12-24	2010-01-29	Astrazeneca Ab	Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
US7105425B1 (en) *	2002-05-16	2006-09-12	Advanced Micro Devices, Inc.	Single electron devices formed by laser thermal annealing
ATE438644T1 (de) *	2002-12-24	2009-08-15	Astrazeneca Ab	Chinazolinderivate
BRPI0409427A (pt) *	2003-04-16	2006-04-18	Astrazeneca Ab	composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
US20060135541A1 (en) *	2003-06-02	2006-06-22	Astrazeneca Ab	(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
US20090036474A1 (en) *	2004-10-12	2009-02-05	Patrick Ple	Quinazoline derivatives for use against cancer
GB0427917D0 (en) *	2004-12-21	2005-01-26	Astrazeneca Ab	Chemical compounds
WO2006129064A1 (en) *	2005-05-28	2006-12-07	Astrazeneca Ab	Quinazolines and their use as aurora kinase inhibitors
GB0601215D0 (en) *	2006-01-21	2006-03-01	Astrazeneca Ab	Chemical compounds
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
GB0609617D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
WO2009074827A2 (en) *	2007-12-12	2009-06-18	Astrazeneca Ab	Combination comprising a mek inhibitor and an aurora kinase inhibitor 188

2002
- 2002-12-20 SI SI200230864T patent/SI1463506T1/sl unknown
- 2002-12-20 ES ES02788214T patent/ES2333702T3/es not_active Expired - Lifetime
- 2002-12-20 PT PT02788214T patent/PT1463506E/pt unknown
- 2002-12-20 DE DE60234125T patent/DE60234125D1/de not_active Expired - Lifetime
- 2002-12-20 PL PL371253A patent/PL211694B1/pl unknown
- 2002-12-20 CN CNB028283058A patent/CN100491372C/zh not_active Expired - Lifetime
- 2002-12-20 AT AT02788214T patent/ATE446093T1/de active
- 2002-12-20 UA UA20040706026A patent/UA82058C2/uk unknown
- 2002-12-20 KR KR1020047010003A patent/KR101029281B1/ko not_active Expired - Lifetime
- 2002-12-20 EP EP02788214A patent/EP1463506B1/en not_active Expired - Lifetime
- 2002-12-20 JP JP2003556068A patent/JP4498741B2/ja not_active Expired - Lifetime
- 2002-12-20 CA CA2471577A patent/CA2471577C/en not_active Expired - Lifetime
- 2002-12-20 HU HU0402454A patent/HU229477B1/hu unknown
- 2002-12-20 NZ NZ533440A patent/NZ533440A/en not_active IP Right Cessation
- 2002-12-20 MX MXPA04006260A patent/MXPA04006260A/es active IP Right Grant
- 2002-12-20 US US10/499,684 patent/US7402585B2/en not_active Expired - Lifetime
- 2002-12-20 RU RU2004122926/04A patent/RU2323215C2/ru active
- 2002-12-20 BR BRPI0215312A patent/BRPI0215312B8/pt not_active IP Right Cessation
- 2002-12-20 AU AU2002353196A patent/AU2002353196B2/en not_active Expired
- 2002-12-20 WO PCT/GB2002/005845 patent/WO2003055491A1/en not_active Ceased
- 2002-12-20 IL IL16254102A patent/IL162541A0/xx unknown
- 2002-12-20 DK DK02788214T patent/DK1463506T3/da active
- 2002-12-23 AR ARP020105081A patent/AR038052A1/es active IP Right Grant
- 2002-12-23 MY MYPI20024859A patent/MY141739A/en unknown
- 2002-12-24 TW TW091137139A patent/TWI335818B/zh not_active IP Right Cessation
- 2002-12-24 UY UY27604A patent/UY27604A1/es not_active Application Discontinuation
2003
- 2003-01-28 SA SA03230531A patent/SA03230531B1/ar unknown
2004
- 2004-06-21 IS IS7328A patent/IS2758B/is unknown
- 2004-06-22 ZA ZA2004/04923A patent/ZA200404923B/en unknown
- 2004-07-23 NO NO20043158A patent/NO328159B1/no not_active IP Right Cessation
2008
- 2008-05-28 US US12/128,479 patent/US20090215770A1/en not_active Abandoned
2009
- 2009-12-17 CY CY20091101316T patent/CY1109681T1/el unknown

Also Published As

Publication number	Publication date
AR038052A1 (es)	2004-12-22
EP1463506B1 (en)	2009-10-21
IS2758B (is)	2011-10-15
IL162541A0 (en)	2005-11-20
KR20040066929A (ko)	2004-07-27
MXPA04006260A (es)	2005-03-31
US20090215770A1 (en)	2009-08-27
DE60234125D1 (de)	2009-12-03
CA2471577A1 (en)	2003-07-10
JP2005525307A (ja)	2005-08-25
PL211694B1 (pl)	2012-06-29
DK1463506T3 (da)	2010-01-11
RU2323215C2 (ru)	2008-04-27
CN100491372C (zh)	2009-05-27
KR101029281B1 (ko)	2011-04-18
SI1463506T1 (sl)	2010-01-29
CY1109681T1 (el)	2014-08-13
WO2003055491A1 (en)	2003-07-10
RU2004122926A (ru)	2005-07-10
PL371253A1 (en)	2005-06-13
US7402585B2 (en)	2008-07-22
BR0215312A (pt)	2004-12-07
US20050070561A1 (en)	2005-03-31
NO328159B1 (no)	2009-12-21
ZA200404923B (en)	2005-11-30
HUP0402454A2 (hu)	2005-03-29
CA2471577C (en)	2011-08-02
SA03230531A (ar)	2005-12-03
CN1620296A (zh)	2005-05-25
MY141739A (en)	2010-06-15
SA03230531B1 (ar)	2008-09-08
AU2002353196B2 (en)	2008-01-17
JP4498741B2 (ja)	2010-07-07
BRPI0215312B1 (pt)	2018-03-27
UY27604A1 (es)	2003-07-31
EP1463506A1 (en)	2004-10-06
HUP0402454A3 (en)	2009-08-28
HU229477B1 (en)	2014-01-28
UA82058C2 (uk)	2008-03-11
AU2002353196A1 (en)	2003-07-15
NZ533440A (en)	2006-08-31
ES2333702T3 (es)	2010-02-26
PT1463506E (pt)	2009-12-10
TWI335818B (en)	2011-01-11
IS7328A (is)	2004-06-21
BRPI0215312B8 (pt)	2021-05-25
ATE446093T1 (de)	2009-11-15
HK1076598A1 (zh)	2006-01-20
TW200410697A (en)	2004-07-01

Publication	Publication Date	Title
NO20043158L (no)	2004-09-16	Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20050636L (no)	2005-02-04	Inhibitorer av tyrosinkinaser
NO20033399D0 (no)	2003-07-30	Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033593L (no)	2003-08-13	Kinazoliner som MMP-13 inhibitorer
DK1667991T3 (da)	2008-08-18	Quinazolinderivater som tyrosinkinaseinhibitorer
DK1317442T3 (da)	2006-02-13	Quinolinonderivater som tyrosinkinaseinhibitorer
SE0701538L (sv)	2007-06-26	Azaspiroalkanderivat som hämmare av metalloproteaser
NO20043726L (no)	2004-11-08	Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
NO20022139L (no)	2002-05-03	Kinazolinderivater som VEGF inhibitorer
DK1438306T3 (da)	2014-06-23	Derivater af UK-2A
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20026010L (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
EE200300459A (et)	2004-02-16	Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
DK1556375T3 (da)	2008-11-03	Flavonderivater som inhibitorer af cyklinafhængige kinaser
NO20033618L (no)	2003-10-15	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
EP1534268A4 (en)	2006-11-02	TYROSINE KINASE INHIBITORS
DK1401828T3 (da)	2006-07-31	N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1178986T3 (da)	2004-07-05	Furanonderivater som inhibitorer af cathepsin S
NO20050563L (no)	2005-01-31	N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20021959L (no)	2002-05-29	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20041968L (no)	2004-05-11	Anvendelse av cystationin
DK1562955T3 (da)	2008-06-02	Quinazolinderivater som Src-tyrosinkinaseinhibitorer
NO20041938L (no)	2004-05-11	Anvendelse av fosfodiesterase IV-inhibitorer
NO20035206L (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer

Legal Events

Date	Code	Title	Description
2023-01-09	MK1K	Patent expired